Data completeness
0/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POVAN (pyrvinium pamoate) is an oral suspension anthelmintic agent indicated for the treatment of pinworm (Enterobius vermicularis) infections. The drug works by disrupting the parasitic worm's energy metabolism, leading to immobilization and expulsion. It is a classic antiparasitic with a long clinical history, now repositioned as a branded oral suspension formulation.
Pre-Launch
As a pre-launch asset, the brand team is small and focused on market entry strategy; significant expansion potential if rapid uptake occurs post-launch.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on POVAN offers exposure to specialty pediatric commercialization and niche market positioning within a Pfizer franchise. The pre-launch phase provides opportunity to shape market strategy, but the mature disease area and generic competition limit long-term career growth potential.
Brand ManagerField Sales Representative
Worked on POVAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.